A Phase 3 interventional study of insulin degludec/insulin aspart in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 49 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-26.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 35th largest by enrollment, is one of 6 that started in 2012, is one of 49 in phase 3, and was the 26th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 394 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 138th largest by enrollment of the 428 interventional ones that give a count, is one of 24 that started in 2012, is one of 187 in phase 3, and was the 270th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Africa, Asia and Europe. The aim of the trial is to compare the efficacy and safety of insulin degludec/insulin aspart and BIAsp 30 (biphasic insulin aspart 30) in insulin naïve subjects with type 2 diabetes.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 394 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec/insulin aspart
Drug: insulin degludec/insulin aspart
Drug pages: Insulin degludec · Insulin Aspart
Administered s.c. (under the skin) twice daily. Dose individually adjusted. Pre-trial metformin treatment to be continued.
Change From Baseline in HbA1c (Glycosylated Haemoglobin)
Change from baseline in HbA1c after 26 weeks of treatment.
Time frame: Week 0, week 26
Change From Baseline in Fasting Plasma Glucose (FPG)
Change from baseline in fasting plasma glucose (FPG) after 26 weeks of treatment.
Time frame: Week 0, week 26
Number of Treatment Emergent Nocturnal (00:01-05:59 am) Severe or Minor Hypoglycaemic Episodes
The pool of severe and minor hypoglycaemic episodes was referred to as confirmed hypoglycaemic episodes, which is presented here. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes were defined as occurring between 00:01 and 05:59 am.
Time frame: Onset on or after the first day of exposure to investigational product and no later than 7 days after last exposure to investigational product
Number of Severe and Minor Treatment Emergent Hypoglycaemic Episodes
The pool of severe and minor hypoglycaemic episodes was referred to as confirmed hypoglycaemic episodes, which is presented here. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.
Time frame: Onset on or after the first day of exposure to investigational product and no later than 7 days after last exposure to investigational product
Change From Baseline in Body Weight
Change from baseline in body weight after 26 weeks of treatment.
Time frame: Week 0, week 26
Responder for HbA1c (Below 7.0%) Without Severe and Minor Treatment Emergent Hypoglycaemic Episodes During the Last 12 Weeks of Treatment Including Only Subjects Exposed for at Least 12 Weeks
Responder for HbA1c (\<7.0%) without severe and minor treatment emergent hypoglycaemic episodes during the last 12 weeks of treatment. Severe + minor hypoglycaemic episodes = confirmed hypoglycaemic episodes. Severe hypoglycaemic episodes: requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes: able to treat her/himself and plasma glucose below 3.1 mmol/L.
Time frame: Week 26
Number of Treatment Emergent AEs (Adverse Events)
A Treatment Emergent Adverse Event (TEAE) was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. Severity was assessed by investigator.
Time frame: Onset on or after the first day of exposure to investigational product and no later than 7 days after exposure to investigational product
The trial was conducted at 47 sites in 10 countries: Algeria (4), Bulgaria (7), Croatia (5), Czech Republic (4), Germany (5), Poland (5), Romania (5), Slovakia (3), Turkey (2), and Ukraine (7).
| Milestone | IDegAsp BID | BIAsp 30 BID |
|---|---|---|
| Started | 197 | 197 |
| Exposed | 196 | 195 |
| Completed | 187 | 184 |
| Not completed | 10 | 13 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Withdrawal criteria | 3 | 0 |
| Withdrew: Unclassified | 5 | 10 |
Change from baseline in HbA1c after 26 weeks of treatment.
| Percent (%) glycosylated haemoglobin | IDegAsp BID | BIAsp 30 BID |
|---|---|---|
| Change From Baseline in HbA1c (Glycosylated Haemoglobin) | -1.85 ± 0.97 | -1.73 ± 0.93 |
Change from baseline in fasting plasma glucose (FPG) after 26 weeks of treatment.
| mmol/L | IDegAsp BID | BIAsp 30 BID |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) | -4.44 ± 2.97 | -3.03 ± 2.90 |
The pool of severe and minor hypoglycaemic episodes was referred to as confirmed hypoglycaemic episodes, which is presented here. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes were defined as occurring between 00:01 and 05:59 am.
| episodes | IDegAsp BID | BIAsp 30 BID |
|---|---|---|
| Number of Treatment Emergent Nocturnal (00:01-05:59 am) Severe or Minor Hypoglycaemic Episodes | 60 | 260 |
The pool of severe and minor hypoglycaemic episodes was referred to as confirmed hypoglycaemic episodes, which is presented here. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.
| episodes | IDegAsp BID | BIAsp 30 BID |
|---|---|---|
| Number of Severe and Minor Treatment Emergent Hypoglycaemic Episodes | 553 | 1221 |
Change from baseline in body weight after 26 weeks of treatment.
| kg | IDegAsp BID | BIAsp 30 BID |
|---|---|---|
| Change From Baseline in Body Weight | 2.8 ± 4.1 | 2.0 ± 4.3 |
Responder for HbA1c (\<7.0%) without severe and minor treatment emergent hypoglycaemic episodes during the last 12 weeks of treatment. Severe + minor hypoglycaemic episodes = confirmed hypoglycaemic episodes. Severe hypoglycaemic episodes: requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes: able to treat her/himself and plasma glucose below 3.1 mmol/L.
| participants | IDegAsp BID | BIAsp 30 BID |
|---|---|---|
| Responder for HbA1c (Below 7.0%) Without Severe and Minor Treatment Emergent Hypoglycaemic Episodes During the Last 12 Weeks of Treatment Including Only Subjects Exposed for at Least 12 Weeks | 77 | 59 |
A Treatment Emergent Adverse Event (TEAE) was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. Severity was assessed by investigator.
| events | IDegAsp BID | BIAsp 30 BID |
|---|---|---|
| Events | 197 | 137 |
| Serious | 20 | 12 |
| Severe | 13 | 8 |
| Moderate | 45 | 27 |
| Mild | 139 | 102 |
| Fatal | 2 | 2 |
Collected over From the first trial-related activity after the subject had signed the informed consent (Week -1) and until post-treatment follow-up period (Week 27).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDegAsp BID | — | 13/196 (6.6%) | 15/196 (7.7%) |
| BIAsp 30 BID | — | 10/195 (5.1%) | 7/195 (3.6%) |
| Event | IDegAsp BID | BIAsp 30 BID |
|---|---|---|
| Myocardial ischaemiaCardiac disorders | 0/196 | 2/195 |
| HypoglycaemiaMetabolism and nutrition disorders | 2/196 | 1/195 |
| Cardiac failureCardiac disorders | 0/196 | 1/195 |
| Coronary artery insufficiencyCardiac disorders | 0/196 | 1/195 |
| Deafness neurosensoryEar and labyrinth disorders | 0/196 | 1/195 |
| Optic ischaemic neuropathyEye disorders | 0/196 | 1/195 |
| Non-cardiac chest painGeneral disorders | 0/196 | 1/195 |
| Peritonsillar abscessInfections and infestations | 0/196 | 1/195 |
| Foot fractureInjury, poisoning and procedural complications | 0/196 | 1/195 |
| Pancreatic carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/196 | 1/195 |
| Event | IDegAsp BID | BIAsp 30 BID |
|---|---|---|
| NasopharyngitisInfections and infestations | 15/196 | 7/195 |
| Age, Continuous(years) | IDegAsp BID | BIAsp 30 BID | Total |
|---|---|---|---|
| Mean | 59.0 ± 9.5 | 58.8 ± 8.4 | 58.9 ± 8.9 |
| Sex: Female, Male(Participants) | IDegAsp BID | BIAsp 30 BID | Total |
|---|---|---|---|
| Female | 95 | 96 | 191 |
| Male | 102 | 101 | 203 |
| Glycosylated Haemoglobin (HbA1c)(Percent (%) glycosylated haemoglobin) | IDegAsp BID | BIAsp 30 BID | Total |
|---|---|---|---|
| Mean | 8.5 ± 0.8 | 8.3 ± 0.7 | 8.4 ± 0.8 |
| Fasting plasma glucose (FPG)(mmol/L) | IDegAsp BID | BIAsp 30 BID | Total |
|---|---|---|---|
| Mean | 10.5 ± 2.4 | 10.0 ± 2.3 | 10.2 ± 2.3 |
| Body Weight(kg) | IDegAsp BID | BIAsp 30 BID | Total |
|---|---|---|---|
| Mean | 88.0 ± 15.0 | 88.5 ± 14.9 | 88.2 ± 14.9 |
Ran from Jan 2012 to primary completion in Nov 2012, 10 months.
Results were first posted in Nov 2015, 3 years after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 10 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Insulin Aspart